Title :

Atypical thrombosis associated with VaxZevria® (AstraZeneca) vaccine: Data from the French Network of Regional Pharmacovigilance Centres

Author(s) :

Gras-Champel, V. [Auteur]
Liabeuf, S. [Auteur]
Baud, M. [Auteur]
Albucher, J. F. [Auteur]
Benkebil, M. [Auteur]
Boulay, C. [Auteur]
Bron, A. [Auteur]
El Kaddissi, A. [Auteur]
Gautier, Sophie [Auteur]
Centre Régional de PharmacoVigilance Nord-Pas-de-Calais [CHU Lille] [CRPV]
Geeraerts, T. [Auteur]
Girot, Marie [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Grandvuillemin, A. [Auteur]
Laujin, H. [Auteur]
Jonville-Bera, A. P. [Auteur]
Masmoudi, K. [Auteur]
Massardier, E. [Auteur]
Micallef, J. [Auteur]
Mounier, C. [Auteur]
Montastruc, F. [Auteur]
Pariente, A. [Auteur]
Perez, J. [Auteur]
Raposo, N. [Auteur]
Salvo, F. [Auteur]
Valnet-Rabier, M. B. [Auteur]
Vial, T. [Auteur]
Massy, N. [Auteur]

Journal title :

Therapies

Abbreviated title :

Therapie

Volume number :

76

Pages :

P. 369-373

Publication date :

2021-07

ISSN :

1958-5578

English keyword(s) :

VaxZevria (R)
Covid-19 vaccine
Pharmacovigilance
Atypical thrombosis
Thrombopenia
Anti-PF4 antibodies

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Starting in late 2019, the initial cases of a previously unknown form of pneumonia, now referred to as coronavirus disease 2019 (COVID-19), led to a global pandemic. In response, most countries have sought to curb the ...
Show more >Starting in late 2019, the initial cases of a previously unknown form of pneumonia, now referred to as coronavirus disease 2019 (COVID-19), led to a global pandemic. In response, most countries have sought to curb the spread of the virus by imposing periods of lockdown as a function of the national infection rates. By the end of 2020, the advent of vaccines against this severe acute respiratory coronavirus 2 syndrome (SARS-CoV-2) prompted new hope in the global fight against the COVID-19 pandemic. In Europe, mRNA vaccines and adenovirus vector vaccines have received conditional marketing authorizations for active immunization against SARS-CoV-2 in individuals aged 16 and over.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
CHU Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Submission date :

2023-11-15T06:27:09Z
2024-02-20T14:06:38Z